What's Shanghai experience of COVID-19 management?

Official WeChat account of SIFIC | Updated: 2020-03-25 06:45

The Shanghai epidemic prevention and control press conference said: Hydroxychloroquine ranked as the first drug in "Shanghai Plan" therapeutic drugs, Shanghai's experience in diagnosing and treating COVID-19 is worth sharing. Up until March 15, the clinical study of Hydroxychloroquine in treating COVID-19 has enrolled a total of 184 cases, involving 21 hospitals. The preliminary results showed that the Hydroxychloroquine treatment was effective and safer. Just yesterday, Trump announced that Hydroxychloroquine and Remdesivir have been approved by the FDA for special use.

Hydroxychloroquine might be the "special medication", the hope for the public, to reverse the pandemic trend of COVID-19 for real. The scale of the COVID-19 being so large and the impact being so deep, we haven't seen something like this for hundreds years. This outbreak has made us realize that the world is closely connected; no country can be alone; and no one can live without another. Only by working together can we beat the virus.

Following is summary of Pro. Bijie Hu's report on COVID-19. The discussions is based on Chinese National Health Commission Diagnosis and Treatment Protocol (Trial Version 7) and on the consensus of the Shanghai Combined Task Force on COVID-19.


Early detection and prevention of deterioration of COVID-19 Pneumonia

Antiviral treatment and applications

Corticosteroid and antibiotic applications

Maintenance and support of the immune system

Management of Severe Pneumonia and Critical Pneumonia

Diagnostic criteria for COVID-19 Pneumonia

Discharge criteria and RT-PCR re-test positivity

Here in Shanghai, we take the treatment measures of concentrate patients, concentrate experts and concentrate resources to treat COVID-19. We collect all adult cases and collectively put them in Shanghai Public Health Clinical Center for treatment. A total of 300 plus cases were treated.

These cases belong to "Severe Pneumonia" category, they need close clinical monitoring. In recent period, the ratio of severe pneumonia among COVID-19 diagnosed cases has almost diminished to zero. The reason for this result was due to our cumulative experiences in the effective treatment modalities and the application to clinical use. On daily basis, we go through each case as we treat and review their possible clinical & laboratory indicators that would indicate impending deterioration. We have to double our efforts to prevent the occurrence of severe clinical situations. If we could successfully prevent the occurrence of severe cases, we could conserve our medical resources significantly.

|<< Previous 1 2 3 4 5 6 7 Next   >>|

Please feel free to contact us by sending your questions to or commenting on China Daily app. We will ask experts to answer them.

Editor's picks
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349